Krystal Biotech has experienced rapid financial scaling driven by the strong commercial uptake of its flagship treatment, VYJUVEK. The company generates substantial annual product revenues, backed by high-margin global sales that scale consistently each fiscal year. With trailing twelve-month revenues surpassing hundreds of millions of dollars and quarterly product sales continuing to expand across international markets, the company maintains a robust top-line performance that sets it apart from traditional pre-revenue clinical biotech firms. For precise, audited annual revenue figures and granular segment breakdowns, stakeholders can review the company’s official financial reports and annual Form 10-K filings available through the SEC or the investor relations portal.